Condition: Open Angle Glaucoma · Ocular Hypertension · Sponsor: Ocular Therapeutix, Inc.
To assess efficacy, and safety of a single sustained release dose of the OTX-TIC drug product (2 travoprost dose strengths) in subjects with Open Angle Glaucoma (OAG) or Ocular Hypertension (OHT)
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Ocular Therapeutix, Inc. | Dothan, Alabama, United States | — |
| Ocular Therapeutix, Inc. | Huntington Beach, California, United States | — |
| Ocular Therapeutix, Inc. | Irvine, California, United States | — |
| Ocular Therapeutix, Inc. | Los Angeles, California, United States | — |
| Ocular Therapeutix, Inc. | Pasadena, California, United States | — |
| Ocular Therapeutix, Inc. | Petaluma, California, United States | — |
| Ocular Therapeutix, Inc. | Redlands, California, United States | — |
| Ocular Therapeutix, Inc. | Torrance, California, United States | — |
| Ocular Therapeutix, Inc. | Clearwater, Florida, United States | — |
| Ocular Therapeutiux, Inc. | Delray Beach, Florida, United States | — |
| Ocular Therapeutix, Inc. | Fort Myers, Florida, United States | — |
| Ocular Therapeutix, Inc. | Roswell, Georgia, United States | — |
+ 18 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05335122